Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

Warner Chilcott, the makers of Sarafem (fluoxetine hydrochloride), a treatment for Premenstrual Dysphoric Disorder (PMDD), have issued a warning about the risk of neuroleptic malignant syndrome, also known as Tardive Dyskinesia, a condition in which a person develops involuntary movements of his muscles similar to Parkinson’s Disease.

Read the rest of this entry »